PCR-uncorrected day 28

	umber of ACPR / umber of patients			ACPR (95% CI)	Description
Q Nosten, 1993 [27] Nosten, 1993 [27] McGready, 1998b [76] McGready, 1998b [76] McGready, 2002 [79] McGready, 2002 [79] Adam, 2004b [69] Adegnika, 2005 [71]* Bounyasong, 2001 [39] Adam, 2004a [43]	11/16 11/16 86/112 54/88 149/209 14/25 25/26 30/50 29/29 24/24			$\begin{array}{c} 0.69 \ (0.44, \ 0.86) \\ 0.69 \ (0.44, \ 0.86) \\ 0.77 \ (0.68, \ 0.84) \\ 0.61 \ (0.51, \ 0.71) \\ 0.71 \ (0.65, \ 0.77) \\ 0.56 \ (0.37, \ 0.73) \\ 0.96 \ (0.81, \ 0.99) \\ 0.60 \ (0.46, \ 0.72) \\ 1.00 \ (0.88, \ 1.00) \\ 1.00 \ (0.86, \ 1.00) \end{array}$	Q 5 days Q 5 days + spiramyo Primary Retreatment Primary Retreatment Retreatment Q ≥7 days Retreatment
AM Adam, 2004c [70]	28/28		+-•	1.00 (0.88, 1.00)	Retreatment
ASSP Onyamboko, 2011 [60] Kalilani, 2007 [44] Adam, 2006 [72]	23/24 29/39 32/32	•	•	0.96 (0.80, 0.99) 0.74 (0.59, 0.85) 1.00 (0.89, 1.00)	AS 200mg
DP Osarfo, 2017 [52]* Adam, 2012 [59]*	180/199 12/12		+ •	0.90 (0.86, 0.94) 1.00 (0.76, 1.00)	
ASMQ Bounyasong, 2001 [39] Carmona-Fonseca, 2013 Valea, 2014 [63]*	28/28 3 [49] 15/15 24/24			1.00 (0.88, 1.00) 1.00 (0.80, 1.00) 1.00 (0.86, 1.00)	NFDC NFDC FDC
AL Ukah, 2015 [54] Iribhogbe, 2017a [55] Kaye, 2008 [47] Carmona-Fonseca, 2013 Mutagonda, 2016 [67, 68				0.94 (0.86, 0.98) 0.95 (0.83, 0.99) 0.98 (0.90, 1.00) 1.00 (0.80, 1.00) 0.87 (0.78, 0.92)	With milk
ASAQ Osarfo, 2017 [52]* Ukah, 2015 [54] Iribhogbe, 2017a [55] Iribhogbe, 2017b [74] Mutabingwa, 2009 [46] Ndiaye, 2011 [73]*	164/184 64/65 36/37 32/42 68/75 28/28			0.89 (0.84, 0.93) 0.98 (0.92, 1.00) 0.97 (0.86, 1.00) 0.76 (0.61, 0.87) 0.91 (0.82, 0.95) 1.00 (0.88, 1.00)	NFDC (co-blistered) FDC FDC NFDC NFDC FDC FDC
AMMQ Sowunmi, 1998 [38]	22/22			1.00 (0.85, 1.00)	Retreatment
AAP McGready, 2003a [58]	16/16			1.00 (0.81, 1.00)	Retreatment

Proportion of PCR-uncorrected ACPR


Additional file 10 The PCR-uncorrected proportional adequate clinical and parasitological response (ACPR). ACPR with 95% confidence intervals are shown by treatment group and the duration of follow-up. *: ACPR at later follow-up day is available. AAP: artesunate + atovaquone-proguanil, AC: artesunate + clindamycin, AL: artemether-lumefantrine, AM: artemether, AS: artesunate, AQ: amodiaquine, DP: dihydroartemisinin-piperaquine, FDC: fixed dose combination, MQ: mefloquine, NFDC: non-fixed dose combination, Q: quinine, QC: quinine + clindamycin, SP: sulfadoxine-pyrimethamine.

,	12			
	umber of ACPR / umber of patients		ACPR (95% CI)	Description
Q McGready, 2001a [41] Piola, 2010 [48]*	46/47 122/127	-•	0.98 (0.89, 1.00) 0.96 (0.91, 0.98)	Quinine + clindamycin
DP Osarfo, 2017 [52] Adam, 2012 [59]*	167/191 12/12		0.87 (0.82, 0.91) 1.00 (0.76, 1.00)	
ASMQ McGready, 1998a [75] Valea, 2014 [63]*	23/26 24/24		0.88 (0.71, 0.96) 1.00 (0.86, 1.00)	NFDC, retreatment FDC
AL Onyamboko, 2015 [53 Onyamboko, 2015 [53 Piola, 2010 [48]* Mosha, 2014 [65] Nyunt, 2016 [66]		•	0.90 (0.78, 0.95) 0.90 (0.78, 0.95) 0.99 (0.96, 1.00) 0.82 (0.66, 0.91) 0.83 (0.66, 0.93)	Cumulative success, with milk AL5, cumulative succees, with m With milk With milk With milk
ASAQ Osarfo, 2017 [52] Ndiaye, 2011 [73]	156/180 28/28	-	0.87 (0.81, 0.91) 1.00 (0.88, 1.00)	NFDC FDC
AS McGready, 1998a [75] McGready, 2001a [41]		-+	0.90 (0.80, 0.95) 1.00 (0.92, 1.00)	Retreatment
AMMQ McGready, 1998a [75]	2/3 ←		0.67 (0.21, 0.94)	Retreatment
Artemisinins McGready, 2001b [77] McGready, 2001b [77]	214/229 243/310	→	0.93 (0.89, 0.96) 0.78 (0.73, 0.83)	Primary, cumulative success Retreatment, cumulative succes
AAP McGready, 2003b [80]	21/21	+•	1.00 (0.85, 1.00)	Retreatment

Proportion of PCR-uncorrected ACPR

Study	Number of ACPR Number of patien				ACPR (95% CI)	Description
Q						
Adegnika, 2005 [71] 19/41 —	•			0.46 (0.32, 0.61)	day 56
McGready, 2000	[40] 21/32		•		0.66 (0.48, 0.80)	
DP						
Rijken, 2008 [82]	36/47		— •—		0.77 (0.63, 0.86)	Retreatment
Adam, 2012 [59]	12/12			+-•	1.00 (0.76, 1.00)	
Rijken, 2011 [62]	23/24			+	0.96 (0.80, 0.99)	Retreatment
D'Alessandro, 20	16 [50] 653/751		-		0.87 (0.84, 0.89)	
ASMQ						
McGready, 2000	[40] 48/51		_	↓	0.94 (0.84, 0.98)	NFDC
Valea, 2014 [63]	23/24			+•	0.96 (0.80, 0.99)	FDC
D'Alessandro, 20	16 [50] 557/761		-		0.73 (0.70, 0.76)	FDC
AL						
Rulisa, 2012 [83]	1064/1068			•	1.00 (0.99, 1.00)	Retreatment
D'Alessandro, 20	16 [50] 436/824	-			0.53 (0.49, 0.56)	High fat food recommende
ASAQ						
D'Alessandro, 20	16 [50] 642/780		+		0.82 (0.79, 0.85)	FDC
AS						
McGready, 2012	[61] 16/20	_	•	+	0.80 (0.58, 0.92)	28 mg/kg/course
				$\left \right $		
		0.5	0.75 0).9 1		

Additional file continued.



Proportion of PCR-uncorrected ACPR